KARYOPHARM THERAPEUTICS INC (KPTI) Stock Price, Quote, News and Overview
NASDAQ:KPTI - Nasdaq - US48576U2050 - Common Stock - Currency: USD
KPTI Quote, Performance and Key Statistics
4.48
-0.07 (-1.54%)
The current stock price of KPTI is 4.48 USD. In the past month the price decreased by -29.45%. In the past year, price decreased by -69.18%.
KPTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.83 | 323.41B | ||
| AMGN | AMGEN INC | 13.41 | 149.70B | ||
| GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
| ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
| ONC | BEIGENE LTD-ADR | 6.15 | 25.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
| NTRA | NATERA INC | N/A | 22.01B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
| BIIB | BIOGEN INC | 8.06 | 18.69B |
Related stock screener links
About KPTI
Company Profile
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 279 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Company Info
KARYOPHARM THERAPEUTICS INC
85 Wells Avenue, Second Floor
Newton MASSACHUSETTS 02459 US
CEO: Michael G. Kauffman
Employees: 279
Phone: 16176580600
KARYOPHARM THERAPEUTICS INC / KPTI FAQ
What is the stock price of KARYOPHARM THERAPEUTICS INC today?
The current stock price of KPTI is 4.48 USD. The price decreased by -1.54% in the last trading session.
What is the ticker symbol for KARYOPHARM THERAPEUTICS INC stock?
The exchange symbol of KARYOPHARM THERAPEUTICS INC is KPTI and it is listed on the Nasdaq exchange.
On which exchange is KPTI stock listed?
KPTI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KARYOPHARM THERAPEUTICS INC stock?
13 analysts have analysed KPTI and the average price target is 49.62 USD. This implies a price increase of 1007.5% is expected in the next year compared to the current price of 4.48. Check the KARYOPHARM THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KARYOPHARM THERAPEUTICS INC worth?
KARYOPHARM THERAPEUTICS INC (KPTI) has a market capitalization of 38.71M USD. This makes KPTI a Nano Cap stock.
How many employees does KARYOPHARM THERAPEUTICS INC have?
KARYOPHARM THERAPEUTICS INC (KPTI) currently has 279 employees.
What are the support and resistance levels for KARYOPHARM THERAPEUTICS INC (KPTI) stock?
KARYOPHARM THERAPEUTICS INC (KPTI) has a support level at 4.47 and a resistance level at 6.28. Check the full technical report for a detailed analysis of KPTI support and resistance levels.
Is KARYOPHARM THERAPEUTICS INC (KPTI) expected to grow?
The Revenue of KARYOPHARM THERAPEUTICS INC (KPTI) is expected to decline by -2.58% in the next year. Check the estimates tab for more information on the KPTI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KARYOPHARM THERAPEUTICS INC (KPTI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KPTI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KPTI, evaluating the profitability, health, valuation and growth aspects
- KARYOPHARM THERAPEUTICS INC (KPTI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KARYOPHARM THERAPEUTICS INC (KPTI) Sales and EPS estimates to see what analysts future expectations are.
- KARYOPHARM THERAPEUTICS INC (KPTI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KARYOPHARM THERAPEUTICS INC (KPTI) Insider and Institutional Ownership to learn about the owners and their transactions.
- KARYOPHARM THERAPEUTICS INC (KPTI) Stock Chart to make your own analysis
- KARYOPHARM THERAPEUTICS INC (KPTI) Latest news and press-releases to stay up to date.
Does KARYOPHARM THERAPEUTICS INC (KPTI) stock pay dividends?
KPTI does not pay a dividend.
When does KARYOPHARM THERAPEUTICS INC (KPTI) report earnings?
KARYOPHARM THERAPEUTICS INC (KPTI) will report earnings on 2025-08-04, before the market open.
What is the Price/Earnings (PE) ratio of KARYOPHARM THERAPEUTICS INC (KPTI)?
KARYOPHARM THERAPEUTICS INC (KPTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.02).
What is the Short Interest ratio of KARYOPHARM THERAPEUTICS INC (KPTI) stock?
The outstanding short interest for KARYOPHARM THERAPEUTICS INC (KPTI) is 24.71% of its float. Check the ownership tab for more information on the KPTI short interest.
KPTI Technical Analysis
KPTI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KPTI. KPTI may be in some trouble as it scores bad on both profitability and health.
KPTI Financial Highlights
Over the last trailing twelve months KPTI reported a non-GAAP Earnings per Share(EPS) of -8.02. The EPS increased by 57.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KPTI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KPTI. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -45.56% and a revenue growth -2.58% for KPTI